Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6236-6245
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Table 4 Multivariate analysis
| Factors associated with SVR | Comparison | Adjusted OR for SVR | 95%CI | P value | |
| Lower | Upper | ||||
| HCV genotype | 2 vs 1 | 11.40 | 2.8 | 47.3 | < 0.0001 |
| 3 vs 1 | 43.10 | 6.5 | 286.3 | ||
| 4 vs 1 | 10.70 | 2.4 | 48.8 | ||
| Pre-treatment total bilirubin | ≥ 1.5 vs < 1.5 | 0.21 | 0.08 | 0.57 | 0.002 |
| Donor age | Each 10 yr | 0.69 | 0.54 | 0.88 | 0.003 |
| CMV mismatch | Donor +/recipient - | 4.80 | 1.8 | 12.6 | 0.001 |
| vs all others | |||||
| HCV viral load (baseline) | Each 1 million | 0.97 | 0.94 | 0.999 | 0.040 |
| Adjusted HR | |||||
| Pre-treatment ALP | ≥ 150 vs < 150 | 2.01 | 1.18 | 3.43 | 0.010 |
| Pre-treatment total bilirubin | ≥ 1.5 vs < 1.5 | 2.49 | 1.47 | 4.21 | 0.001 |
| Pre-treatment creatinine | ≥ 2 vs < 2 | 5.88 | 2.68 | 12.92 | < 0.001 |
- Citation: Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol 2015; 21(20): 6236-6245
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6236.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6236